Estrella Immunopharma closed at $0.41 on Nov 5, down 7.53%, 86.0% below its 52-week closing high. Volume of 162.9K shares was 0.03× its 20-day average (below normal).
Split-adjusted performance: -2.2% over one month, -67.7% over six months, -82.1% over one year.
Short interest was 599.6K shares at the Oct 15 settlement, up 180.2% from the prior report (4.0% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ESLAEstrella Immunopharma | $0.4101 | −7.53% | −67.7% | — | — | — | $17.8M | |
| BKHABlack Hawk Acquisition | $4.50 | −19.21% | — | — | — | — | $18.7M | Compare |
| BSEMBioStem Technologies | $1.04 | −9.57% | — | — | — | — | $19.4M | Compare |
| PLURPluri | $1.19 | −3.26% | −64.4% | −15.8% | −1755.2% | — | $16.1M | Compare |
| JSPRJasper Therapeutics | $0.4692 | −8.20% | −48.3% | — | — | — | $15.6M | Compare |
| ABOSAcumen Pharmaceuticals | $0.2138 | −1.16% | −91.3% | — | — | — | $15.5M | Compare |
| ATYRaTyr Pharma | $6.03 | −2.43% | −83.6% | — | — | — | $15.1M | Compare |
| DYAIDyadic International | $0.3401 | −7.25% | −54.3% | −0.6% | −221.0% | — | $13.6M | Compare |
| BCDABioCardia | $0.8900 | −2.53% | −18.3% | — | — | — | $13.5M | Compare |
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
